Medical Disclaimer: This website does not provide medical advice. Content is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any supplement. Read full disclaimer →

RESEARCH NEWS · QUARTERLY ROUNDUP

5 Ayurveda Clinical Trials Published in 2025-2026 You Should Know About

Q: What is the most important Ayurveda trial of 2025?

The 2025 Mhaskar meta-analysis in Phytotherapy Research splitting Ashwagandha's cortisol-reduction findings from perceived-stress findings is the most methodologically careful evidence synthesis on the herb published in years.

New Ayurveda research is published every month. Almost no consumer-facing publication tracks it. This is the first of HerbVerdict's quarterly roundups — five recent trials worth a serious read, presented with full study card detail and honest limitations.

By Ash · Research Editor · Updated April 28, 2026 · 12 min read

How I picked these five. I searched PubMed for clinical trials on Ayurvedic herbs published between January 2025 and April 2026, prioritised studies with n > 50 and clear methodology, then chose five that show editorial range — positive findings, mixed findings, surprising findings. This is curation, not cherry-picking. For our framework on how to evaluate any individual trial, see How to Read a Clinical Trial.

The five trials at a glance

Trial 1 — Ashwagandha in team-sport athletes during pre-season

RCT n = 56 42 days 2026

Tiu et al., 2026 — KSM-66 in pre-season athletes

Journal	Nutrients
Design	Randomised double-blind placebo-controlled in 56 team-sport athletes (rugby, water polo, football)
Dose	600 mg/day KSM-66 Ashwagandha root extract for 42 days during pre-season training
Key finding	Significant group × time interaction for cortisol in females and cortisone in males. Ashwagandha attenuated stress-related hormonal increases seen in placebo group during intense training.
Limitation	Single-centre. Athletic context — does not generalise to sedentary populations. Industry-funded (Ixoreal Biomed, KSM-66 manufacturer).
Source	Nutrients 2026

Why this trial matters. It extends ashwagandha's cortisol-modulation evidence from sedentary stressed-adult populations into elite athletic contexts. The finding is consistent with the broader cortisol-reduction literature but operationalises it in a population where stress-related hormonal increase is a real performance issue. The honest read. This is industry-funded research using the manufacturer's branded extract — that's worth flagging. It is also a methodologically reasonable trial with measured cortisol endpoints rather than just self-report scales. The finding adds modest weight to KSM-66's cortisol-reduction profile.

For our full Ashwagandha verdict, see [Ashwagandha Evidence Scorecard](/herbs/ashwagandha).

Trial 2 — Curcumin network meta-analysis in knee osteoarthritis

Network meta-analysis 17 RCTs 2024

Wang et al., 2024 — Turmeric products in knee OA

Journal	Phytomedicine
Design	Systematic review and network meta-analysis of 17 RCTs comparing different turmeric/curcumin preparations vs placebo and active comparators
Key finding	All turmeric preparations significantly reduced WOMAC pain scores. Bioavailability-enhanced curcumin formulations showed the largest effect sizes (mean difference −2.47).
Limitation	Heterogeneity across underlying trials in formulations, doses, and durations. Most underlying trials were 8-12 weeks; longer-term safety inference limited.
Source	PMC 12309109

Why this trial matters. Network meta-analyses are particularly useful for comparing multiple intervention versions (different curcumin formulations) when not all of them have been tested head-to-head in single trials. The finding consolidates the case for bioavailability-enhanced curcumin as a meaningful intervention in knee OA pain. The honest read. This is the strongest single piece of evidence currently available for any Ayurvedic herb in any clinical use case. It's the foundation for our PROVEN verdict on curcumin for knee OA pain. The caveat: the trial used branded extracts (Meriva, Theracurmin, similar) that most Indian retail turmeric products do not match.

For our full Turmeric verdict, see [Turmeric Evidence Scorecard](/herbs/turmeric).

Trial 3 — Ashwagandha cortisol meta-analysis with mixed findings

Meta-analysis 9 RCTs pooled 2025

Mhaskar et al., 2025 — Ashwagandha cortisol vs perceived stress

Journal	Phytotherapy Research
Design	Systematic review and meta-analysis pooling RCTs measuring both cortisol and perceived stress outcomes
Key finding	Statistically significant cortisol reduction across pooled trials. No significant pooled effect on Perceived Stress Scale once heterogeneity was corrected.
Limitation	Mixed extracts (KSM-66, Sensoril, generic) across underlying trials. Most underlying trials had high risk of bias on at least one methodological dimension.
Source	PubMed 40746175

Why this trial matters. This is the most important Ayurveda paper of 2025 in my view, and it's the one that gets cited least by Ashwagandha marketing. It splits the cortisol-reduction finding (which holds up in pooled analysis) from the perceived-stress finding (which doesn't). Two well-conducted meta-analyses on the same outcome reaching different conclusions is informative, not failure. The honest read. This finding shifted Ashwagandha's verdict on HerbVerdict from a comfortable "could be Proven" to a careful "PROMISING with caveats." Cortisol moves measurably; whether people feel less stressed is more contested. Both can be true at the same time.

For our full Ashwagandha verdict, see [Ashwagandha Evidence Scorecard](/herbs/ashwagandha).

Trial 4 — Boswellia 5-day onset in knee OA

Multi-centre RCT 3-arm parallel 2024

Karlapudi et al., 2024 — Standardised Boswellia, rapid onset

Journal	Frontiers in Pharmacology
Design	Multi-centre, three-arm, parallel-group RCT testing standardised Boswellia extract vs placebo
Key finding	Clinically meaningful improvements in WOMAC pain by day 5; effects strengthened through week 12.
Limitation	Industry-funded (Boswellin Super manufacturer). Use of branded extract limits generalisability to other Boswellia preparations.
Source	Frontiers Pharmacology 2024

Why this trial matters. Most Boswellia OA trials show effects emerging at 8-12 weeks. The 5-day onset finding here is a meaningful methodological data point — it suggests certain standardised preparations may work faster than the broader Boswellia literature implies. The honest read. Industry-funded trials of branded extracts are common and not automatically biased. The 5-day finding warrants independent replication before being treated as a category-wide property of Boswellia. For now, it's a promising addition to the evidence base supporting our PROVEN verdict on Boswellia for knee OA.

For our full Boswellia verdict, see [Boswellia Evidence Scorecard](/herbs/boswellia).

Trial 5 — Triphala in constipated colon microbiota

In-vitro colon model 2025

2025 — Triphala in mildly constipated human colon microbiota

Journal	Journal of Functional Foods
Design	Dynamic in-vitro colon model using stool donations from mildly constipated individuals
Key finding	Triphala extract increased Akkermansia muciniphila and decreased Bifidobacterium spp. Increased phenolic species and antioxidant potential. Reduced ammonia production.
Limitation	In-vitro model — does not establish in-vivo efficacy in actual constipated humans. Trade-off between Akkermansia (generally health-associated) and Bifidobacterium decrease (generally health-associated) is not clearly net-positive.
Source	Journal of Functional Foods 2025

Why this trial matters. It's the most recent piece of work extending Triphala's microbiota-modulation evidence into a more clinically relevant population (constipated individuals rather than healthy controls). The in-vitro design is a limitation but the methodology is rigorous. The honest read. I included this trial specifically because it's interesting biology with mixed implications. The Akkermansia increase is positive; the Bifidobacterium decrease is uncertain. This is the kind of result that adds nuance rather than confirming a simple positive narrative — which is more representative of what real research often looks like.

For our full Triphala verdict, see [Triphala Evidence Scorecard](/herbs/triphala).

What patterns emerge from these five trials

Looking across these five recent trials, three patterns stand out.

Pattern 1 — Ashwagandha continues to dominate the Ayurveda research investment landscape. Two of five trials in this roundup are on Ashwagandha. The herb has the strongest research-investment ecosystem because branded extract manufacturers (KSM-66, Sensoril, Shoden) are funding ongoing trials. Other Ayurvedic herbs receive less sustained research investment. Pattern 2 — Methodological sophistication is increasing. The 2024 Wang network meta-analysis on curcumin and the 2025 Mhaskar meta-analysis on ashwagandha represent more sophisticated evidence synthesis than was typical 5-10 years ago. Multi-centre designs and pre-registered protocols are becoming more common. Pattern 3 — Mixed findings are getting published. The 2025 Mhaskar meta-analysis splitting cortisol and perceived-stress outcomes is the kind of nuanced result that older Ayurveda research culture sometimes suppressed. Publication of mixed findings is healthy for the field even when it complicates marketing narratives.

What's missing from the 2025-2026 research landscape

Three meaningful gaps I'd like to see filled in the next 12-24 months.

Long-term safety follow-up studies. Most Ayurvedic herb RCTs run 8-12 weeks. The recent ashwagandha and giloy hepatotoxicity case-series literature has flagged safety questions that 12-week trials cannot answer. We need 6-12 month prospective cohort studies tracking adverse events. Replication studies outside India. Most Ayurvedic herb research is conducted in India. Replication in non-Indian clinical populations is the strongest test of whether findings generalise. The WHO–AYUSH MoU framework may eventually facilitate this; it has not yet at meaningful scale. Specific-product clinical trials for major Indian retail SKUs. Currently, no Indian retail Ayurveda product (Himalaya, Patanjali, Dabur, Baidyanath, Kapiva, etc.) has a published clinical trial of the specific SKU as it is sold to consumers. Brands rely on broader herb-category evidence. Specific-product trials would meaningfully professionalise the category.

These are research-investment questions, not biology questions. They will get filled if the commercial and academic incentives align.

How to follow new Ayurveda research yourself

Three specific approaches I recommend for readers who want to track the field directly.

Set up a PubMed alert. Visit pubmed.ncbi.nlm.nih.gov, run searches like `(ashwagandha OR turmeric OR boswellia OR triphala) AND (randomized OR clinical trial)`, and use the "Create Alert" feature to receive new-publication notifications by email. Alerts are free and run automatically. Follow CCRAS publications. The Central Council for Research in Ayurvedic Sciences publishes its own research output through their website (ccras.nic.in) and their in-house journal JRAS. New CCRAS papers are sometimes not picked up by general PubMed searches.

**Check the Journal of Ayurveda and Integrative Medicine monthly. This is one of the best-quality Ayurvedic medicine journals globally, and it publishes new research frequently. Open-access content is freely available.

These three approaches together cover roughly 80% of meaningful new Ayurvedic clinical research. The other 20% appears in international journals (Phytomedicine, Frontiers in Pharmacology, similar) where general PubMed alerts will catch it.

What I'll be tracking for the next quarterly roundup

Three lines of research I'm specifically watching.

The continuing post-pandemic hepatotoxicity follow-up literature on Indian Ayurvedic herbs. The 2022 multi-centre Giloy and 2023 multi-centre ashwagandha case series have raised pharmacovigilance questions that subsequent prospective work should help resolve.

Multi-centre trials of compound Ayurvedic formulations (Chyawanprash, Triphala, Brahmi-Bringaraj). These are more clinically relevant than single-herb trials for actual Indian consumer use.

Bioavailability and formulation research. Different curcumin formulations, different ashwagandha extracts, and different shilajit preparations all deliver materially different active doses. Pharmacokinetic clarity helps consumers compare products.

I publish quarterly roundups every three months. Bookmark this section if you want to track Ayurveda research without doing the PubMed searches yourself.

What's notably absent from the 2025-2026 trial landscape

I want to flag what didn't get published this year, because absence of evidence is itself a useful editorial signal.
No major Shilajit trial. Despite Shilajit's massive consumer market in India and globally, no significant new RCT on the herb was published in 2025-2026 at the methodological quality of the trials I covered above. The herb's commercial growth continues to outpace its research investment. No major Tulsi multi-centre trial. The 2022 HolixerTM Tulsi trial remains the strongest recent piece of evidence. No comparable replication or extension landed in 2025-2026. The category needs a multi-centre stress-reduction trial to consolidate the evidence base. No specific-SKU trials for major Indian retail brands. Himalaya, Patanjali, Dabur, Baidyanath, Kapiva — none has published a trial of their specific commercial SKUs as sold to consumers. Trials continue to use research-grade extracts that consumers cannot directly purchase. No long-term safety follow-up to the 2022-2023 hepatotoxicity case-series. The Giloy and ashwagandha hepatotoxicity case-series literature has not been followed up by prospective cohort studies tracking long-term safety in real-world Indian populations. This is a meaningful pharmacovigilance gap. No major neem skin-condition multi-centre RCT. Neem's antimicrobial preclinical evidence remains stronger than its human dermatology trial base. The 2025-2026 window saw small studies but no field-defining multi-centre work.
These gaps are research-investment patterns rather than scientific impossibilities. Whether they get filled in 2026-2027 depends on which research programmes get funded.

How to interpret a "no significant difference" finding

This is a common reader question and worth a section because it shows up in three of the five trials I covered.

A "no significant difference" finding means the trial did not detect a statistically significant difference between intervention and control groups on the measured outcome. It does NOT mean "the intervention doesn't work."

Several explanations are possible for a null finding. The intervention genuinely doesn't work — this is one possibility but not the only one. The trial was underpowered to detect a real but small effect — sample size was too small. The wrong outcome was measured — the intervention may work for a different outcome than the one tested. The dose, duration, or formulation was wrong — research often goes through multiple iterations to find effective parameters. The placebo response was unusually strong — making it hard to detect intervention-specific effects.

A single "no significant difference" finding in a small trial is a data point, not a conclusion. Multiple independent null findings at meaningful sample size are stronger evidence against efficacy.

For Ayurveda research specifically, null findings should be read carefully because the trial base for many herbs is small and underpowered. A null finding in an n=30 trial is much weaker than a null finding in a meta-analysis of multiple RCTs combined to n=400.

What I'll be tracking in the July 2026 quarterly roundup

Three lines of research I'm specifically watching.
Multi-centre replications of single-trial findings. Several of the 2024-2025 trials covered above produced positive findings at single centres. Replication at multiple sites is the most informative next step. Prospective hepatotoxicity surveillance. Following the 2022 Giloy and 2023 ashwagandha case-series literature, prospective cohort studies tracking long-term liver outcomes in herb users would meaningfully advance the safety conversation. Branded Indian retail product trials.** If any wave-three Indian DTC brand commissions a clinical trial of their specific commercial SKU, it would be a meaningful first for the Indian Ayurveda retail category.

I publish quarterly roundups every three months. The July 2026 edition will track all three of these and whatever else lands in the meantime.

What this roundup teaches about Ayurveda research methodology

A pattern observation from working through these five trials worth flagging.

Ayurveda research methodology is improving year-over-year. The 2024-2026 trial designs are noticeably more rigorous on several dimensions compared to 5-10 years ago. Multi-centre designs are more common. Pre-registered protocols on CTRI and ClinicalTrials.gov are now standard for serious research. Industry funding disclosure is more transparent.

What hasn't improved as much: sample sizes remain modest, trial durations remain short (most still 8-12 weeks), and replication outside Indian research centres remains rare.

The trajectory matters because methodological maturation is the path through which traditional medicine research becomes integrated into mainstream clinical evidence. The 2025-2026 vintage of Ayurveda research is meaningfully better than the 2015-2016 vintage. Whether this trajectory continues over the next decade depends on research-investment patterns and the regulatory environment.

For consumers, this trajectory has practical implications. The evidence base supporting Ayurvedic herbs is growing, slowly and unevenly, but in the right direction. Verdicts that were "Limited" five years ago might move to "Promising" in the next five. Verdicts that are "Promising" now might move to "Proven" with continued replication. This is what a maturing research field looks like.

Frequently asked questions

What is the most important Ayurveda trial of 2025?

The 2025 Mhaskar et al. meta-analysis in Phytotherapy Research splitting Ashwagandha's cortisol-reduction findings (which held up) from perceived-stress findings (which didn't). It's the most methodologically careful evidence synthesis on the herb published in years.

Are Ayurveda clinical trials mostly conducted in India?

Yes. The vast majority of Ayurvedic herb RCTs are conducted at Indian research centres, often with industry funding from branded extract manufacturers. Replication in non-Indian populations is one of the field's biggest research gaps.

How often is new Ayurveda research published?

New peer-reviewed Ayurveda clinical research is published roughly monthly. Most of it is small single-centre work; methodologically rigorous multi-centre RCTs are less frequent (perhaps 4-6 per year across all major Ayurvedic herbs combined).

Which Ayurvedic herb has the most active research right now?

Ashwagandha, by a substantial margin. The herb has the strongest commercial backing (KSM-66, Sensoril, Shoden branded extracts) which funds ongoing trial programmes. Curcumin/turmeric is second.

How do I know if a recent Ayurveda trial is reliable?

Check the journal (PubMed-indexed is baseline), the trial design (RCT preferred, multi-centre stronger), the sample size (n > 50 minimum for meaningful conclusions), and the funding source (industry funding warrants closer scrutiny). Our How to Read a Clinical Trial guide walks through this in detail.